BioCentury | Jun 21, 2019

VC pair seeds cancer play Yukin, seeks preclinical readout

...timelines related to the company's research. Tracon Inc. (NASDAQ:TCON) returned rights to MAP3K14-targeting program TRC694 (JNJ-64290694...
BioCentury | Aug 8, 2018
Distillery Therapeutics


...models of liver disease. Johnson & Johnson and Tracon Pharmaceuticals Inc. have the MAP3K14 inhibitor TRC694...
BioCentury | Oct 3, 2016
Company News

J&J, Tracon deal

...unit granted Tracon exclusive, worldwide development rights to TRC253 (formerly JNJ-63576253 ) and TRC694 (formerly JNJ-64290694... reacquire TRC694 up through completion of a proof-of-concept trial. If Tracon continues development of TRC694...
...eligible for up to $60 million in development and regulatory milestones, plus low single-digit royalties. TRC694...
Items per page:
1 - 3 of 3